MedTrace Logo

F-18 Rhodamine 6G PET Imaging for Myocardial Blood Flow

NCT04528758 · Status: SUSPENDED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-08-24

No results posted yet for this study

Summary

Use of novel radio-pharmaceutical Rhodamine 6G to determine myocardial blood flow

Conditions

Interventions

DRUG

Rhodamine 6G

Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow

Sponsors & Collaborators

Principal Investigators

  • Robert Gropler, MD · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2024-06-30
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528758 on ClinicalTrials.gov